Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 1.00 |
| ▸ | TTK | P33981 | 6/20 | 1.00 |
| ▸ | INSR | P06213 | 5/20 | 1.00 |
| ▸ | GAK | O14976 | 3/20 | 1.00 |
| ▸ | IGF1R | P08069 | 3/20 | 1.00 |
| ▸ | LTK | P29376 | 3/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 3/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 3/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 3/20 | 1.00 |
| ▸ | INSRR | P14616 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 3/20 | 0.64 |
| ▸ | FLT3 | P36888 | 3/20 | 0.64 |
| ▸ | NPM1 | P06748 | 3/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | ERN1 | O75460 | 2/20 | 0.54 |
| ▸ | STK10 | O94804 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051419 | 1.00 | ALK (1.00) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL29446184 | 1.00 | ALK (1.00) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4058870 | 0.94 | ALK (0.89) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4052384 | 0.93 | ALK (0.87) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4046968 | 0.93 | ALK (0.86) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4056762 | 0.92 | ALK (0.85) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4051438 | 0.92 | ALK (0.84) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4052796 | 0.91 | ALK (0.83) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4050498 | 0.90 | ALK (0.81) | ALKTTKINSRGAKIGF1R | |
| SCHEMBL4052581 | 0.89 | ALK (0.80) | ALKTTKINSRGAKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | claimed |
| CN-119318655-A | Application of Mps1-IN-1 as iron death inhibitor and IN preparing medicine for preventing and treating iron death related diseases | 合肥综合性国家科学中心大健康研究院 | 2025-01-17 | — | — | CN | claimed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-20250295686-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. | 2025-09-25 | — | — | US | disclosed |
| CN-119318655-B | Application of Mps1-IN-1 as iron death inhibitor and IN preparing medicine for preventing and treating iron death related diseases | 合肥综合性国家科学中心大健康研究院 | 2025-09-23 | — | — | CN | disclosed |
| CN-119318655-B | Application of Mps1-IN-1 as iron death inhibitor and IN preparing medicine for preventing and treating iron death related diseases | 合肥综合性国家科学中心大健康研究院 | 2025-09-23 | — | — | CN | disclosed |
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | disclosed |
| CN-119318655-A | Application of Mps1-IN-1 as iron death inhibitor and IN preparing medicine for preventing and treating iron death related diseases | 合肥综合性国家科学中心大健康研究院 | 2025-01-17 | — | — | CN | disclosed |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-05-02 | — | — | US | disclosed |
| US-20230414628-A1 | METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 | RAMESH SANATH KUMAR (US) | 2023-12-28 | — | — | US | disclosed |
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| WO-2023069943-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-114592061-A | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-107567503-B | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | STAMBP, HSPBP1, ECPAS | ALK 1995/4885TTK 2298/4885INSR 4218/4885 |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | TTBK1, CTNNB1, TTK | ALK 622/4885TTK 3/4885INSR 4523/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | ALK 3706/4885TTK 2279/4885INSR 87/4885 |
| US-20230414628-A1 | METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 | GPX4, GPX1, MPO | ALK 4858/4885TTK 4505/4885INSR 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.